Literature DB >> 1799660

The site of activation of factor X by cancer procoagulant.

S G Gordon1, A M Mourad.   

Abstract

Cancer procoagulant (CP) is a cysteine proteinase found in a variety of malignant cells and tissues and in human amnion-chorion tissue. It initiates coagulation by activating factor X. However, the amino acid sequence of the substrate protein that determines the cleavage site of cysteine proteinases is different from that of the serine proteinases that normally activate factor X, such as factor IXa, VIIa and Russell's Viper Venom (RVV). Therefore, it was of interest to determine the site of cleavage of human factor X by CP. Purified CP was incubated with purified factor X and the reaction mixture was electrophoresed on a 10% Tris-tricine SDS-PAGE gel. The proteins were electroeluted on to a polyvinylidene difluoride (PVDF) membrane, and stained with Coomassie blue. The heavy chain of activated factor X was cut out of the PVDF membrane and sequenced with an Applied Biosystems 477A with on-line HPLC. The primary cleavage sequence was Asp-Ala-Ala-Asp-Leu-Asp-Pro-; two other secondary sequences Ser-Ile-Thr-Trp-Lys-Pro- and Glu-Asn-Pro-Phe-Asp-Leu were found. The penultimate amino acid on the carbonyl side of the hydrolysed amide bond plays a critical role for the recognition of the cleavage site of cysteine proteinases. These data indicate that the penultimate amino acid for the primary cleavage site of factor X by CP is proline-20 and for the secondary sites, proline-13 and proline-28. This is in contrast to arginine-52 that determines the specificity of the cleavage by normal serine proteinase activation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1799660     DOI: 10.1097/00001721-199112000-00007

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  10 in total

Review 1.  Non-tissue factor procoagulants in cancer cells.

Authors:  S G Gordon; M Chelladurai
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

Review 2.  The hypercoagulable state of malignancy: pathogenesis and current debate.

Authors:  Graham J Caine; Paul S Stonelake; Gregory Y H Lip; Sean T Kehoe
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

3.  Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leucocyte initiation of coagulation.

Authors:  J Plescia; D C Altieri
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

Review 4.  Pathogenesis of thrombosis in patients with malignancy.

Authors:  A Falanga; M B Donati
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

5.  Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.

Authors:  Malgorzata Kamocka; Morris Pollard; Mark Suckow; Wojciech P Mielicki; Elliot D Rosen
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

6.  Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.

Authors:  L R Jalbert; E D Rosen; L Moons; J C Chan; P Carmeliet; D Collen; F J Castellino
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

7.  Multiple embolic cerebral infarcts as the first manifestation of metastatic ovarian cancer.

Authors:  Laura M Bond; Darko Skrobo
Journal:  BMJ Case Rep       Date:  2015-10-06

8.  In Vitro Screening of Synthetic Fluorogenic Substrates for Detection of Cancer Procoagulant Activity.

Authors:  Jason Krause; Carminita L Frost
Journal:  Protein J       Date:  2018-04       Impact factor: 2.371

9.  The proteolytic profile of human cancer procoagulant suggests that it promotes cancer metastasis at the level of activation rather than degradation.

Authors:  Nalise Low Ah Kee; Jason Krause; Gregory L Blatch; Koji Muramoto; Kazuo Sakka; Makiko Sakka; Ryno J Naudé; Leona Wagner; Raik Wolf; Jens-Ulrich Rahfeld; Hans-Ulrich Demuth; Wojciech P Mielicki; Carminita L Frost
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

Review 10.  The cancer stem cell: evidence for its origin as an injured autoreactive T cell.

Authors:  Peter Grandics
Journal:  Mol Cancer       Date:  2006-02-14       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.